Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 5/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20889907 | 0.86 | IDH1 (0.35) | P2RX7MBOAT4ADRB1IDH1IDH2 | |
| SCHEMBL8190474 | 0.84 | KCNH2 (0.46) | P2RX7MBOAT4ADRB1IDH1IDH2 | |
| SCHEMBL18494297 | 0.81 | KCNH2 (0.56) | P2RX7MBOAT4ADRB1IDH1IDH2 | |
| SCHEMBL830319 | 0.81 | KCNH2 (0.36) | MBOAT4HRH4 | |
| SCHEMBL24620449 | 0.80 | KCNH2 (0.33) | MBOAT4ADRB1 | |
| SCHEMBL10202962 | 0.80 | IDH1 (0.46) | P2RX7MBOAT4ADRB1IDH1IDH2 | |
| SCHEMBL21503525 | 0.80 | ADRB1 (0.40) | P2RX7MBOAT4ADRB1IDH1IDH2 | |
| SCHEMBL2258434 | 0.80 | P2RX7 (0.41) | P2RX7MBOAT4ADRB1IDH1IDH2 | |
| SCHEMBL13181472 | 0.79 | MBOAT4 (0.41) | P2RX7MBOAT4HRH4MAOBHTR2C | |
| SCHEMBL317403 | 0.79 | P2RX7 (0.47) | P2RX7MBOAT4ADRB1IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | NXERA PHARMA UK LIMITED (GB) | 2024-08-06 | — | — | US | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023220247-A1 | LRRK2 INHIBITORS | INTERLINE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | BOEHRINGER INGELHEIM INT (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11766443-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-26 | — | — | US | disclosed |
| US-11766443-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-26 | — | — | US | disclosed |
| US-11737463-B2 | Pyridine and pyrazine compounds | BASF SE (DE) | 2023-08-29 | — | — | US | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20080070902-A1 | Cinnamide Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080021024-A1 | Metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-01-24 | — | — | US | disclosed |
| WO-2007139856-A2 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139860-A2 | HETEROBICYLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED | 2007-11-15 | — | — | US | disclosed |
| WO-2007079199-A2 | SUBSTITUTED BIS-AMIDE METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS, HOLDING, INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| WO-2007071738-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155737-A1 | Heterobicyclic metalloprotease inhibitors | ADAMTS4, ADAMTS1, ADAMTS5 | P2RX7 4003/4885MBOAT4 2339/4885ADRB1 4853/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | P2RX7 2998/4885MBOAT4 1196/4885ADRB1 636/4885 |
| US-11737463-B2 | Pyridine and pyrazine compounds | NDUFS5, IL5, NDUFS4 | P2RX7 42/4885MBOAT4 4772/4885ADRB1 2428/4885 |
| US-20070264196-A1 | Modulators of ATP-binding cassette transporters | CFTR, ABCB1, ABCC2 | P2RX7 277/4885MBOAT4 1874/4885ADRB1 218/4885 |
| US-11766443-B2 | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | PTAFR, PDGFRA, F3 | P2RX7 60/4885MBOAT4 3105/4885ADRB1 829/4885 |
| US-20080070902-A1 | Cinnamide Compound | C1S, CCR1, CNR1 | P2RX7 657/4885MBOAT4 4791/4885ADRB1 16/4885 |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2A, ADORA2B, ADORA1 | P2RX7 49/4885MBOAT4 3491/4885ADRB1 21/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | P2RX7 2326/4885MBOAT4 4367/4885ADRB1 2811/4885 |
| US-20230355638-A1 | Cyclopentathiophene Carboxamide Derivatives as Platelet Activating Factor Receptor Antagonists | PTAFR, PDGFRA, F3 | P2RX7 60/4885MBOAT4 3105/4885ADRB1 829/4885 |
| US-20080021024-A1 | Metalloprotease inhibitors | MMP2, MMP9, MMP3 | P2RX7 2879/4885MBOAT4 3251/4885ADRB1 2843/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | P2RX7 3795/4885MBOAT4 2357/4885ADRB1 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.